Ampullary Cancer Ampullary Cancer [Member] Ampullary Cancer Olumiant® Olumiant [Member] Olumiant [Member] Hedging Designation [Domain] Hedging Designation [Domain] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Fair value of CVR liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability 1.000% Notes due 2022 1.000% Notes Due June 2, 2022 [Member] 1.000% Notes Due June 2, 2022 [Member] Lebrikizumab Lebrikizumab [Member] Lebrikizumab [Member] Short-term investments, debt securities Debt Securities, Available-for-sale, Current Neuroscience Neuroscience [Member] Revenue to unaffiliated customers, Neuroscience Interest cost Defined Benefit Plan, Interest Cost Employee compensation Employee-related Liabilities, Current Interest rate contracts Interest Rate Contract [Member] Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Entity Address, Address Line One Entity Address, Address Line One Lycia Therapeutics, Inc. Lycia Therapeutics, Inc. [Member] Lycia Therapeutics, Inc. Other Diabetes Other Diabetes [Member] Other Diabetes [Member] Dermira Dermira, Inc. [Member] Dermira, Inc. [Member] Equity securities Equity Securities, FV-NI, Current Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than - 2021) Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent Schedule of amounts recorded for contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Prior service benefits, net Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member] Employee benefit trust Common Stock, Shares Held in Employee Trust Other noncurrent assets Other Assets, Noncurrent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Description of Derivative Risk Management Derivatives, Policy [Policy Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flow hedges: Cash Flow Hedge [Abstract] Cash Flow Hedge [Abstract] Schedule of other–net, (income) expense Schedule of Other Nonoperating Income (Expense) [Table Text Block] Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. [Member] Rigel Pharmaceuticals, Inc. Marketable equity securities Marketable Securities [Member] Marketable Securities [Member] Summary the contractual maturities of our investments in debt securities measured at fair value Debt Securities, Available-for-sale [Table Text Block] Schedule of reclassifications out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Limited initial market entry, supply term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term Fair Value Hedging Fair Value Hedging [Member] Document Fiscal Year Focus Document Fiscal Year Focus Foreign Currency Translation Gains (Losses) Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Royalty Agreement Terms Royalty Agreement Terms [Member] Deferred income taxes assumed Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquired IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Stock repurchase program, remaining authorized amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Dividends payable Dividends Payable, Current Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Cash Flow Hedging Cash Flow Hedging [Member] Summary certain fair value information, liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Accrued retirement benefits (Note 8) Liability, Defined Benefit Plan, Noncurrent Assets Assets [Abstract] Merus N.V. Merus N.V. [Member] Merus N.V. Asset impairment (recovery) and other special charges Asset Impairment Charges (Recoveries) And Other Special Charges Asset Impairment Charges (Recoveries) And Other Special Charges Southern District of California Southern District Of California [Member] Southern District Of California Derivatives used in net investment hedge, net of tax Derivatives used in Net Investment Hedge, Net of Tax Junshi Biosciences Junshi Biosciences [Member] Junshi Biosciences Schedule of asset acquisitions Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block] Evox Therapeutics Limited Evox Therapeutics [Member] Evox Therapeutics Employee Litigation Employee Litigation [Member] Employee Litigation [Member] Entity Address, City or Town Entity Address, City or Town Damages awarded, value Loss Contingency, Damages Awarded, Value Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Number of decisions affirmed Loss Contingency, Number Of Decisions Affirmed Loss Contingency, Number Of Decisions Affirmed China CHINA Other Liabilities Liabilities, Noncurrent [Abstract] Alternative investments, unfunded commitments, payment period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period Contingencies Commitments and Contingencies Disclosure [Text Block] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Plaintiff Allegations [Axis] Plaintiff Allegations [Axis] Plaintiff Allegations Innovent Biologics, Inc. Innovent Biologics, Inc. [Member] Innovent Biologics, Inc. Other Neuroscience Other Neuroscience [Member] Other Neuroscience [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Interactive Data Current Entity Interactive Data Current Number of claimants Loss Contingency, Number Of Claimants Loss Contingency, Number Of Claimants Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Net change in short-term borrowings Repayments of Short-term Debt Brazil BRAZIL Basic (in dollars per share) Earnings Per Share, Basic Byetta Byetta [Member] Byetta Number of pending lawsuits Loss Contingency, Pending Claims, Number Other foreign countries Other Foreign Countries [Member] Other Foreign Countries [Member] Revenue Revenue from Contract with Customer [Text Block] Potential achievements Collaborative Arrangement, Rights and Obligations, Rights (Obligations) Terms or rights and obligations under collaborative arrangements. Cash acquired Cash Acquired from Acquisition Document Type Document Type Basaglar® Basaglar Basaglar [Member] Basaglar [Member] Prepaid expenses and other Prepaid Expense, Current Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Kumquat Biosciences Inc. Kumquat Biosciences Inc. [Member] Kumquat Biosciences Inc. Fair Value Measurement [Domain] Fair Value Measurement [Domain] Entity Current Reporting Status Entity Current Reporting Status Contingent value right, monthly reduction (in cents per share) Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Number of plaintiffs Loss Contingency, Number of Plaintiffs Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Purchase price Business Combination, Consideration Transferred Other, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Number of patents Loss Contingency, Number Of Patents Loss Contingency, Number Of Patents Activity related to our available-for-sale securities Gain (Loss) on Securities [Table Text Block] Long-term debt, including current portion Long-term debt, including current portion Long-term Debt Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Precision Biosciences, Inc. Precision Biosciences, Inc. [Member] Precision Biosciences, Inc. Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total liabilities and equity Liabilities and Equity Available-for-sale, percentage of nonperforming assets Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets U.S. government and agency securities US Government Agencies Debt Securities [Member] Taltz® Taltz [Member] Taltz [Member] Intangible asset impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Liabilities and Equity Liabilities and Equity [Abstract] Forward-starting interest rate swaps Interest Rate Swap [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] 3.95% Notes Due 2049 3.95% Notes Due 2049 [Member] 3.95% Notes Due 2049 Verzenio® Verzenio [Member] Verzenio [Member] Other current liabilities Derivative Liability, Current Purchase of treasury shares Treasury Stock, Value, Acquired, Cost Method Mortgage-backed securities Collateralized Mortgage Backed Securities [Member] Equity securities, net unrealized gains (losses) Net investment gains Equity Securities, FV-NI, Gain (Loss) 4.15% Notes Due 2059 4.15% Notes Due 2059 [Member] 4.15% Notes Due 2059 Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Cost Portion at Other than Fair Value Measurement [Member] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other changes in operating assets and liabilities, net of acquisitions and divestitures Increase (Decrease) in Other Operating Assets and Liabilities, Net Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Marketing, selling, and administrative Selling, General and Administrative Expense Retirement benefit plans Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Unrealized gross gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Pancreatitis Pancreatitis [Member] Pancreatitis Other receivables Derivative Asset, Current More Than 10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Equity method investments Equity Method And Other Investments [Member] Equity Method and Other Investments [Member] Trading Symbol Trading Symbol Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Weiler v. Takeda Canada Inc. et al. Whyte Et Al. V. Eli Lilly Et Al. [Member] Whyte Et Al. V. Eli Lilly Et Al. Deferred tax assets Deferred Income Tax Assets, Net Current Liabilities Liabilities, Current [Abstract] Cash paid for acquisitions, net of cash acquired (Note 3) Cash paid, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Other Oncology Other Oncology [Member] Other Oncology [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Employee Benefit Trust Trust for Benefit of Employees [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Foreign currency-denominated notes Hedged Fixed Rate Debt [Member] Hedged Fixed-Rate Debt [Member] Asahi Kasei Pharma Corporation Asahi Kasei Pharma Corporation [Member] Asahi Kasei Pharma Corporation Common stock Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Other–net, (income) expense (Note 11) Other–net, (income) expense Nonoperating Income (Expense) Acquired in-process research and development (Note 3) Acquired in-process research and development The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) Retiree Health Benefit Plans Other Postretirement Benefits Plan [Member] Commitments and Contingencies (Note 9) Commitments and Contingencies Accumulated other comprehensive loss (Note 10) Accumulated Other Comprehensive Income (Loss), Net of Tax Fair value, by balance sheet grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Inventory write-down Inventory Write-down Long-term income taxes payable Accrued Income Taxes, Noncurrent Acquisitions Business Combination Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Fair value hedges: Fair Value Hedge [Abstract] Fair Value Hedge [Abstract] Document Period End Date Document Period End Date Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member] Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Class of Stock [Axis] Class of Stock [Axis] Alimta® Alimta [Member] Alimta [Member] Entity Registrant Name Entity Registrant Name Collaborative Arrangements and Non-collaborative Arrangements [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Swap Swiss Francs to U.S. Dollars Swap Swiss Francs To U.S. Dollars [Member] Swap Swiss Francs To U.S. Dollars [Member] Net purchases of property and equipment Payments to Acquire Productive Assets Financial Instrument [Axis] Financial Instrument [Axis] Cash dividend declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Revenue Revenue from Contract with Customer, Excluding Assessed Tax Erbitux® Erbitux [Member] Erbitux [Member] Dividends paid Payments of Dividends 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] MiNA Therapeutics Limited MiNA Therapeutics Limited [Member] MiNA Therapeutics Limited Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Carrying Amount Reported Value Measurement [Member] ProQR Therapeutics N.V. ProQR Therapeutics N.V. [Member] ProQR Therapeutics N.V. Proceeds from sales and maturities of short-term investments Proceeds from Sale of Short-term Investments Interest income Investment Income, Interest Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Common Stock Common Stock [Member] Purchases of noncurrent investments Payments to Acquire Long-term Investments Costs, expenses, and other Cost of sales, operating expenses, and other-net Cost of sales, operating expenses, and other-net Unrealized gross losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Buy US Dollar Sell Chinese Yuan Buy US Dollar Sell Chinese Yuan [Member] Buy US Dollar Sell Chinese Yuan Collaborations and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Immunology Immunology [Member] Immunology [Member] Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Product Liability Product Liability [Member] Product Liability Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents (Note 6) Cash and Cash Equivalents, at Carrying Value Domicile of Litigation [Axis] Domicile Of Litigation [Axis] Domicile Of Litigation Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Milestone Payments, Contingent Upon Initiation of Phase I Trial Milestone Payments, Contingent Upon Initiation Of Phase I Trial [Member] Milestone Payments, Contingent Upon Initiation Of Phase I Trial Common Stock in Treasury Treasury Stock [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Derivative, notional amount Derivative, Notional Amount Other–net, (income) expense Other (income) expense Other Nonoperating Income (Expense) Other investing activities, net Payments for (Proceeds from) Other Investing Activities Other current liabilities Other Liabilities, Current Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Number of claims dismissed Litigation, Claims Dismissed, Number Litigation, Claims Dismissed, Number Realized gross gains on sales Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Available for Sale Securities and Equity Securities, FV-NI, Realized Gain Schedule of significant milestones and revenue recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Effective Portion of Cash Flow Hedges Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Legal Entity [Axis] Legal Entity [Axis] Payment for debt extinguishment Payment for Debt Extinguishment or Debt Prepayment Cost Japan JAPAN Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total Eli Lilly and Company shareholders’ equity Stockholders' Equity Attributable to Parent Other Other Product, Total [Member] Other Product, Total [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Debt extinguishment loss (Note 6) Debt extinguishment loss Gain (Loss) on Extinguishment of Debt Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member] Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. Purchases of common stock Payments for Repurchase of Common Stock Business acquisition, share price (in dollars per share) Business Acquisition, Share Price Schedule of components of other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Proceeds from sales Proceeds from Sale of Equity and Available for Sale Securities Proceeds from Sale of Equity and Available for Sale Securities Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Weiler v. Takeda Canada Inc. et al. Weiler V. Takeda Canada Inc. Et Al. [Member] Weiler V. Takeda Canada Inc. Et Al. Other noncurrent assets Derivative Asset, Noncurrent Collaborative arrangement, rights and obligations, percentage (up to) Collaborative Arrangement, Rights and Obligations Percent Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. Interest expense Interest Expense Debt instrument, face amount Debt Instrument, Face Amount Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Net change in short-term borrowings Proceeds from Short-term Debt Trulicity® Trulicity [Member] [Member] Trulicity [Member] [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Acquisition date fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Humalog, Humulin and Forteo Humalog, Humulin, And Forteo [Member] Humalog, Humulin, And Forteo City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Purchases of in-process research and development Purchased in-process research and development The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS). Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Cyramza® Cyramza [Member] Cyramza [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Litigation Case Type [Domain] Litigation Case [Domain] Milestone Payments, Sales-based Milestone Payments, Sales-based [Member] Milestone Payments, Sales-based [Member] Diabetes Diabetes [Member] Diabetes [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of the amounts recognized for assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Cross-currency interest rate swaps Cross Currency Interest Rate Contract [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Net investment gains Gain (Loss) on Investments Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Various State Domiciles Various State Domiciles [Member] Various State Domiciles Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Other Other Product [Member] Other Product [Member] Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Buy British Pounds and Sell U.S. Dollars Buy British Pound and Sell US Dollars [Member] Buy British Pound and Sell US Dollars [Member] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Realized gross losses on sales Available for sale Securities and Equity Securities, FV-NI, Realized Loss Available for sale Securities and Equity Securities, FV-NI, Realized Loss Protomer Technologies Inc. Protomer Technologies Inc. [Member] Protomer Technologies Inc. Short-term investments (Note 6) Short-term Investments Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Income taxes (Note 7) Tax benefit Income Tax Expense (Benefit) Petra Petra Pharma Corporation [Member] Petra Pharma Corporation Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020) Accounts Receivable, after Allowance for Credit Loss, Current Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total current assets Assets, Current Effect from interest rate contracts Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Asset Acquisition [Table] Asset Acquisition [Table] Inventories Inventory, Net Epp v. Takeda Canada Inc. et al. Epp V. Takeda Canada Inc. Et Al. [Member] Epp V. Takeda Canada Inc. Et Al. Acquisitions Asset Acquisition [Text Block] Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Contingent value right, additional price per share (up to) (in dollars per share) Business Acquisition, Contingent Value Right, Additional Price Per Share Business Acquisition, Contingent Value Right, Additional Price Per Share Product and Service [Axis] Product and Service [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Other–Net, (Income) Expense Other Income and Other Expense Disclosure [Text Block] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Equity Component [Domain] Equity Component [Domain] Other Stockholders' Equity, Other Cymbalta® Cymbalta [Member] Cymbalta [Member] Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Milestone Payments, Capitalized as Intangible Assets Milestone Payments, Capitalized As Intangible Assets [Member] Milestone Payments, Capitalized As Intangible Assets Noncurrent investments, debt securities Debt Securities, Available-for-sale, Noncurrent Schedule of effects of risk-management instruments were recognized in other–net, (income) expense Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Total Debt Securities, Available-for-sale Contingent value right, additional price per share, aggregate amount Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Retirement of treasury shares Treasury Stock, Retired, Cost Method, Amount Entity Address, State or Province Entity Address, State or Province Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Information [Table] Document Information [Table] Fair value of securities in an unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Entity [Domain] Entity [Domain] Purchases of short-term investments Payments to Acquire Short-term Investments Retirement Benefits Retirement Benefits [Text Block] Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Asset impairment, restructuring, and other special charges (Note 5) Total asset impairment, restructuring, and other special charges Restructuring, Settlement and Impairment Provisions Unrealized Net Gains (Losses) on Securities Unrealized net gains/losses on securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Sitryx Therapeutics Limited Sitryx Therapeutics Limited [Member] Sitryx Therapeutics Limited [Member] Benefit (provision) for income taxes allocated to other comprehensive income (loss) items Other Comprehensive Income (Loss), Tax Total assets Assets Equity method investments Other Long-term Investments Geographical [Domain] Geographical [Domain] Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Non-CHINA Non-CHINA [Member] Non-CHINA Product and Service [Domain] Product and Service [Domain] Noncontrolling Interests Noncontrolling Interest [Member] Research and development Research and Development Expense Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative Contract [Domain] Derivative Contract [Domain] Contingent consideration liability, other noncurrent liabilities Business Combination, Contingent Consideration, Liability Total other liabilities Liabilities, Noncurrent Other Immunology Other Immunology [Member] Other Immunology [Member] Alternative investments, unfunded commitments Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Derivative liability, notional amount Derivative Liability, Notional Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] 1.625% Notes due 2043 1.625% Notes Due 2043 [Member] 1.625% Notes Due 2043 Entity Tax Identification Number Entity Tax Identification Number Other receivables Other Receivables, Net, Current Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Geographical [Axis] Geographical [Axis] Number of patents, claims dismissed Loss Contingency, Number Of Patents, Claims Dismissed Loss Contingency, Number Of Patents, Claims Dismissed Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Los Angeles Los Angeles [Member] Los Angeles Net product revenue Product [Member] Service cost Defined Benefit Plan, Service Cost Net investment hedges Net Investment Hedging [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] COVID-19 Antibodies COVID-19 Antibodies [Member] COVID-19 Antibodies Recognized actuarial loss Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit Fair value of securities in an unrealized gain position Debt Securities, Available-for-sale, Unrealized Gain Position Debt Securities, Available-for-sale, Unrealized Gain Position Outside U.S. Non-US [Member] Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contract liabilities Contract with Customer, Liability Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Cost of common stock in treasury Treasury Stock, Value Shares used in calculation of earnings per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Actuarial losses, net Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Deferred tax liabilities Deferred Income Tax Liabilities, Net Other noncurrent liabilities Derivative Liability, Noncurrent Foreign Currency Denominated Debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 0.500% Notes due 2033 .5000% Notes Due 2033 [Member] .5000% Notes Due 2033 Corporate debt securities Corporate Debt Securities [Member] Financial Instruments Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Emgality Patent Litigation Emgality Patent Litigation [Member] Emgality Patent Litigation [Member] Summary certain fair value information, assets Fair Value, Assets Measured on Recurring Basis [Table Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] The components of the charges included in asset impairment, restructuring, and other special charges Restructuring and Related Costs [Table Text Block] 1.125% Notes due 2051 1.125% Notes Due 2051 [Member] 1.125% Notes Due 2051 Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Summary of the fair value of available-for-sale securities in an unrealized gain or loss position Unrealized Gain (Loss) on Investments [Table Text Block] Investments (Note 6) Noncurrent investments Long-term Investments 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] Financial Instruments [Domain] Financial Instruments [Domain] 6-10 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Retirement of treasury shares (in shares) Treasury Stock, Shares, Retired Proceeds from sales of noncurrent investments Proceeds from Sale of Long-term Investments Cost of sales Cost of Goods and Services Sold Insulin Insulin [Member] Insulin Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Actos Actos [Member] Actos Acquired IPR&D Expense Payments to Acquire Intangible Assets Domicile of Litigation [Domain] Domicile Of Litigation [Domain] Domicile Of Litigation Sales returns, rebates, and discounts Sales Returns and Allowances [Member] Eli Lilly and Company Shareholders’ Equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Tyvyt® TYVYT [Member] TYVYT Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020) Property, Plant and Equipment, Net Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Pancreatic Cancer or Thyroid Cancer Pancreatic Cancer Or Thyroid Cancer [Member] Pancreatic Cancer Or Thyroid Cancer Long-term debt assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Other noncurrent liabilities Other Liabilities, Noncurrent Purchase of treasury shares (in shares) Treasury Stock, Shares, Acquired Repayments of long-term debt Repayments of long-term debt Repayments of Long-term Debt Number of sites jointly and severally liable for cleanup (fewer than) Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup Earnings per share: Earnings Per Share [Abstract] Oncology Oncology [Member] Revenue to unaffiliated customers, Oncology Milestone Payments, Success-based Regulatory and Sales-based Milestone Payments, Success-based Regulatory And Sales-based [Member] Milestone Payments, Success-based Regulatory And Sales-based Emgality® Emgality [Member] Emgality [Member] Document Quarterly Report Document Quarterly Report Milestone Payments, Development and Regulatory Milestone Payments, Development and Regulatory [Member] Milestone Payments, Development and Regulatory [Member] Revenue (Note 2) Revenue Revenues Effective portion of cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Net amount reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] Severance Severance Costs Foreign currency exchange contracts Foreign Exchange Contract [Member] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Sales rebates and discounts Sales rebates and discounts Sales rebates and discounts Costs, expenses, and other: Costs and Expenses [Abstract] Dr Reddy's Lab Dr Reddy's Lab [Member] Dr Reddy's Lab [Member] Long-term debt Long-term Debt, Excluding Current Maturities Asset Acquisition [Domain] Asset Acquisition [Domain] Total Derivative Instruments, Gain (Loss) Recognized Derivative Instruments, Gain (Loss) Recognized Europe Europe [Member] Cialis® Cialis [Member] Cialis [Member] Document Fiscal Period Focus Document Fiscal Period Focus Effective income tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Other securities, noncurrent investments Other Equity Securities [Member] Other Equity Securities [Member] Other securities, current investments Other Debt Obligations [Member] Net income (loss) Total reclassifications, net of tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Short-term borrowings and current maturities of long-term debt Debt, Current Common Stock (no par value) Common Class A [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Cash dividend declared Dividends U.S. UNITED STATES Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Income taxes payable Taxes Payable, Current Current Assets Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Collaboration and other revenue Collaboration and Other Revenue [Member] Collaboration and Other Revenue [Member] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Amount of receivable derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income (loss), net of tax (Note 10) Net other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Consideration transferred, number of contingent value rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights Business Combination, Consideration Transferred, Number Of Contingent Value Rights 1.375% Notes due 2061 1.375% Notes Due 2061 [Member] 1.375% Notes Due 2061 Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Schedule of net pension and retiree health benefit (income) cost Schedule of Net Benefit Costs [Table Text Block] 3.375% Notes Due 2029 3.375% Notes Due 2029 [Member] 3.375% Notes Due 2029 Measurement Basis [Axis] Measurement Basis [Axis] Prevail Therapeutics Inc. Prevail Therapeutics Inc. [Member] Prevail Therapeutics Inc. Humulin® Humulin [Member] Humulin [Member] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Jardiance Jardiance [Member] Jardiance [Member] Humalog® Humalog [Member] Humalog [Member] Plaintiff Allegations [Domain] Plaintiff Allegations [Domain] Plaintiff Allegations Number of patents ruled unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Loss Contingency, Number Of Patents Ruled Unpatentable Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Collaboration and other revenue associated with prior period transfers of intellectual property Royalty [Member] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Issuance of stock under employee stock plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative asset, notional amount Derivative Asset, Notional Amount Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Total current liabilities Liabilities, Current Effect from hedged fixed-rate debt Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Forteo® Forteo [Member] Forteo [Member] Class of Stock [Domain] Class of Stock [Domain] Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Trajenta Trajenta (BI) [Member] Trajenta (BI) [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Loss Contingencies [Table] Loss Contingencies [Table] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Roche Roche [Member] Roche [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Information [Line Items] Document Information [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Buy U.S. Dollars Sell Japanese Yen Buy US dollar Sell Japanese Yen [Member] Buy US dollar Sell Japanese Yen [Member] Buy Euros Sell U.S. Dollars Buy Euro Sell Us Dollar [Member] Foreign Currency Forward Commitment to Buy euro Sell US dollar Statement [Table] Statement [Table] Buy U.S. Dollars Sell Euros Buy Us Dollar Sell Euro [Member] Foreign Currency Forward commitment to Buy US dollar Sell euro Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Asset-backed securities Asset-backed Securities [Member] Swap U.S. Dollars to Euro Swap U.S. Dollars To Euro [Member] Swap U.S. Dollars To Euro [Member] Asset Impairment, Restructuring, and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Cash and cash equivalents at January 1 Cash and Cash Equivalents at September 30 Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cover [Abstract] Cover [Abstract] Goodwill Goodwill Extinguishment of debt, amount Extinguishment of Debt, Amount Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Milestone Payments, Contingent Upon Achieving Clinical Proof of Concept Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept [Member] Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Defined Benefit Pension Plans Pension Plan [Member] Less Than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted Description of Derivative Activity Volume Percent Description of Derivative Activity Volume Percent AbCellera AbCellera Biologics Inc. [Member] AbCellera Biologics Inc. [Member] Zyprexa® Zyprexa [Member] Zyprexa [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]